Final audited revenue rose 45 percent from a year earlier to 1.39 trillion won ($953 million), while operating profit jumped 86.3 percent to 451.8 billion won, the biosimilar maker said in a regulatory filing.
Both figures topped the preliminary numbers released on July 3, by about 93.7 billion won and 21.8 billion won respectively.
Sales of newer products soared 76 percent year-on-year, lifting their share of total biologics revenue to 65 percent, up from the 60 percent-plus cited in the preliminary report.
The company, which has launched 11 biosimilars globally, aims to build an 18-product portfolio by 2030, adding cancer and autoimmune treatments. It reaffirmed full-year targets of 5.3 trillion won in sales and 1.8 trillion won in operating profit, and said it now expects to exceed them.
"This quarter confirmed our cash-generating power and business competitiveness, having achieved an operating margin above 30 percent even after absorbing R&D investment for future growth," said a Celltrion spokesperson, adding the company would keep reinvesting biosimilar cash flow into new drugs.
Shares of Celltrion traded at 182,900 won per stock on 9:44 a.m., 2.96 percent higher than the previous session.
Copyright ⓒ Aju Press All rights reserved.
